Stay updated on EYP-1901 in NPDR Clinical Trial
Sign up to get notified when there's something new on the EYP-1901 in NPDR Clinical Trial page.

Latest updates to the EYP-1901 in NPDR Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2 and removed notices about government funding lapse and operating status (including Revision: v3.4.1). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a government-funding notice on the page and updated the revision tag from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check28 days agoChange DetectedThe page now displays a glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, replacing Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page shows a revision update: Revision: v3.3.4 added and Revision: v3.3.3 removed. No study details, eligibility criteria, locations, or outcome measures appear to be changed.SummaryDifference0.0%

- Check64 days agoChange DetectedA new Locations section has been added, listing EyePoint Investigative Sites across Arizona, California, Connecticut, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts, Nevada, New Jersey, New York, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Virginia, and Washington. The page revision is v3.3.3.SummaryDifference2%

- Check85 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; page content and layout appear unchanged.SummaryDifference0.0%

Stay in the know with updates to EYP-1901 in NPDR Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EYP-1901 in NPDR Clinical Trial page.